Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorpheniramine + midazolam
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intranasal, Intravenous, Intradermal
01
Overview
This represents a drug interaction rather than an intentional combination product. Chlorpheniramine is a histamine H1 receptor antagonist used for allergic conditions, while midazolam is a benzodiazepine used for sedation, anxiolysis, and seizure management. When used together, these medications can increase the risk of CNS depression and sedation.
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on chlorpheniramine + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorpheniramine + midazolam.